Claims for Patent: 10,010,585

✉ Email this page to a colleague

Summary for Patent: 10,010,585

Title:	Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
Abstract:	Methods to reduce the proliferation of vestibular schwannoma (VS) cells and/or provide neuroprotection to reduce the risk of sensorineural hearing loss (SNHL), vestibular dysfunction and facial nerve paralysis in subjects with VS. The methods can include one or more of decreasing TNF-.alpha. activity or expression; decreasing NF-.kappa.B expression or activity; decreasing COX-2 expression or activity; administering FGF2; decreasing HGF expression or activity; or decreasing c-Met expression or activity.
Inventor(s):	Stankovic; Konstantina (Boston, MA), Dilwali; Sonam (Dallas, TX)
Assignee:	Massachusetts Eye and Ear Infirmary (Boston, MA)
Application Number:	14/741,332
Patent Claims:	1. A method of treating a subject having vestibular schwannoma, the method comprising identifying a subject having a vestibular schwannoma and administering to the ear of the subject a therapeutically effective amount of a TNF.alpha. inhibitor by direct delivery into the inner ear. 2. A method of reducing the rate of vestibular schwannoma tumor growth in a subject, the method comprising identifying a subject having a vestibular schwannoma and administering to the ear of the subject a therapeutically effective amount of a TNF.alpha. inhibitor by direct delivery into the inner ear. 3. The method of claim 1, wherein the TNF.alpha. inhibitor is selected from the group consisting of: adalimumab, infliximab, golimumab, etanercept, and certolizumab. 4. The method of claim 1, wherein the local administration is injection through the ear drum. 5. The method of claim 2, wherein the local administration is direct delivery into the inner ear.

Details for Patent 10,010,585

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	⤷ Subscribe	2034-06-16
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Subscribe	2034-06-16
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Subscribe	2034-06-16
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Subscribe	2034-06-16
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Subscribe	2034-06-16
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Subscribe	2034-06-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.